Jolanta Kunikowska

List of Publications by Year
in descending order

87	2,171	279798 23	254184 43
papers	citations	h-index	g-index

96	96	96	2105
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Diagnostic Performance and Clinical Impact of ⁶⁸Ga-PSMA-11 PET/CT Imaging in Early Relapsed Prostate Cancer After Radical Therapy: A Prospective Multicenter Study (IAEA-PSMA Study). Journal of Nuclear Medicine, 2022, 63, 240-247.	5.0	28
2	EANM position on the in-house preparation of radiopharmaceuticals. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1095-1098.	6.4	12
3	Expression of glutamate carboxypeptidase II in the glial tumor recurrence evaluated in vivo using radionuclide imaging. Scientific Reports, 2022, 12, 652.	3.3	7
4	Challenges in theragnostics. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2022, 65, .	0.7	1
5	[68Ga]Ga-PSMA Versus [18F]PSMA Positron Emission Tomography/Computed Tomography in the Staging of Primary and Recurrent Prostate Cancer. A Systematic Review of the Literature. European Urology Oncology, 2022, 5, 273-282.	5.4	37
6	Gender issues in the nuclear medicine community: results from a survey promoted by the EANM Women Empowerment Task Force. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2106-2112.	6.4	5
7	TheranosticsÂâ€“ present and future. Bio-Algorithms and Med-Systems, 2022, 17, 213-220.	2.4	7
8	Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2300-2309.	6.4	20
9	Joint EANM, SNMMI, and IAEA Enabling Guide: How to Set up a Theranostics Center. Journal of Nuclear Medicine, 2022, 63, 1836-1843.	5.0	5
10	Ga-68-PSMA-11 PET/CT in Patients with Biochemical Recurrence of Prostate Cancer after Primary Treatment with Curative Intentâ€"Impact of Delayed Imaging. Journal of Clinical Medicine, 2022, 11, 3311.	2.4	5
11	EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy. European Urology Oncology, 2022, 5, 530-536.	5.4	20
12	Diagnostic Accuracy of PET/CT or PET/MRI Using PSMA-Targeting Radiopharmaceuticals in High-Grade Gliomas: A Systematic Review and a Bivariate Meta-Analysis. Diagnostics, 2022, 12, 1665.	2.6	11
13	[68 Ga]Ga-Prostate-Specific Membrane Antigen PET/CT: a novel method for imaging patients with hepatocellular carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 883-892.	6.4	24
14	The Safety and Efficacy of the Repeated PRRT with [90Y]Y/[177Lu]Lu-DOTATATE in Patients with NET. International Journal of Endocrinology, 2021, 2021, 1-10.	1.5	12
15	EANM Focus 3: The International Conference on Molecular Imaging and Theranostics in Neuroendocrine Tumoursâ€"the consensus in a nutshell. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1276-1277.	6.4	4
16	Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. European Journal of Cancer, 2021, 146, 56-73.	2.8	120
17	Calcification as a cause of potential false-positive findings in bone scintigraphy verified with [68Ga]Ga-PSMA-11 PET/CT - a case report. Polish Archives of Internal Medicine, 2021, 131, 473-475.	0.4	0
18	A rare cause of chronic diarrhoea: a diagnosis to keep in mind. Endokrynologia Polska, 2021, 72, 187-188.	1.0	0

#	Article	IF	Citations
19	Dose escalation study of targeted alpha therapy with [225Ac]Ac-DOTA-substance P in recurrence glioblastoma â€“ safety and efficacy. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3595-3605.	6.4	19
20	Women in nuclear medicine. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2678-2679.	6.4	10
21	Impact of the COVID-19 pandemic on nuclear medicine departments in Europe. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3361-3364.	6.4	6
22	Myelofibrosis Pattern in 68Ga-PSMA PET/CT of a Patient With Recurrence Prostate Cancer. Clinical Nuclear Medicine, 2021, Publish Ahead of Print, .	1.3	1
23	Familial SDHB gene mutation in disseminated non-hypoxia-related malignant paraganglioma treated with [⁹⁰Y]Y/[¹⁷⁷Lu]Lu-DOTATATE. Intractable and Rare Diseases Research, 2021, 10, 207-213.	0.9	0
24	Gender balance in the editorial board of nuclear medicine journals. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3749-3750.	6.4	2
25	Detection of clinically silent brain lesions in [18F]FDG PET/CT study in oncological patients: analysis of over 10,000 studies. Scientific Reports, 2021, 11, 18293.	3.3	5
26	Nuclear medicine theranostics comes of age. Lancet Oncology, The, 2021, 22, 1497-1498.	10.7	11
27	Dosimetry for Radiopharmaceutical Therapy: The European Perspective. Journal of Nuclear Medicine, 2021, 62, 73S-79S.	5.0	7
28	68Gaâ€“Prostate-Specific Membrane Antigen-11 PET/CT. Clinical Nuclear Medicine, 2020, 45, 11-18.	1.3	48
29	68Ga-PSMA PET/CT in Recurrence Prostate Cancer. Should We Perform Delayed Image in Cases of Negative 60 Minutes Postinjection Examination?. Clinical Nuclear Medicine, 2020, 45, e213-e214.	1.3	4
30	Targeted Î±-Emitter Therapy of Neuroendocrine Tumors. Seminars in Nuclear Medicine, 2020, 50, 171-176.	4.6	30
31	225Ac- and 213Bi-Substance P Analogues for Glioma Therapy. Seminars in Nuclear Medicine, 2020, 50, 141-151.	4.6	34
32	Teaching nuclear medicine in the pandemicâ€”a new challenge for the faculty. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2075-2077.	6.4	6
33	Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?. Journal of Nuclear Medicine, 2020, 61, 1094-1095.	5.0	6
34	Sequential delayed [18â€‰F]FDG PET/CT examinations in the pharynx. Scientific Reports, 2020, 10, 2910.	3.3	7
35	Tumor uptake in glioblastoma multiforme after IV injection of [177Lu]Lu-PSMA-617. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1605-1606.	6.4	31
36	Tandem peptide receptor radionuclide therapy using 90Y/177Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experience. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 922-933.	6.4	31

#	Article	IF	Citations
37	Effect of Peptide Receptor Radionuclide Therapy (PRRT) with tandem isotopes â€“ [90Y]Y/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on qualification [18F]FDG PET/CT in Polish multicenter experience â€“ do we need [18F]FDG. Endokrynologia Polska, 2020, 71, 240-248.	1.0	6
38	Parathyroid imaging with [99mTc]Tc-MIBI SPECT/CT â€" unexpected findings of bone marrow involvement of non-Hodgkinâ€™s lymphoma. Endokrynologia Polska, 2020, 71, 271-272.	1.0	0
39	Safety and Therapeutic Efficacy of 225Ac-DOTA-Substance PÂfor Therapy of Brain Tumors. Journal of Medical Imaging and Radiation Sciences, 2019, 50, S91-S92.	0.3	2
40	Safety and efficacy of targeted alpha therapy with 213Bi-DOTA-substance P in recurrent glioblastoma. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 614-622.	6.4	69
41	Liver transplantation as an option of treatment for a giant primary hepatic neuroendocrine tumour. Endokrynologia Polska, 2019, 70, 520-521.	1.0	1
42	Glioblastoma multiforme: another potential application for 68Ga-PSMA PET/CT as a guide for targeted therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 886-887.	6.4	29
43	Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with 213Bi-substance P analogue. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1636-1644.	6.4	75
44	Tele NEN â€" zastosowanie telemedycyny w postÄ™powaniu w nowotworach neuroendokrynnych na przykÅ‚adzie NET uchyÅ‚ka Meckela. Endokrynologia Polska, 2018, 69, 313-317.	1.0	3
45	Simultaneous breast cancer and DLBCL lymphoma â€" role of PET/CT examination with 18F-FDG and 18F-FES. Nuclear Medicine Review, 2018, 21, 113-114.	0.5	3
46	Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18Fâ€“DOPA. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1588-1601.	6.4	319
47	Long-term results and tolerability of tandem peptide receptor radionuclide therapy with 90Y/177Lu-DOTATATE in neuroendocrine tumors with respect to the primary location: a 10-year study. Annals of Nuclear Medicine, 2017, 31, 347-356.	2.2	47
48	Optimizing Somatostatin Receptor Imaging in Patients With Neuroendocrine Tumors. Clinical Nuclear Medicine, 2017, 42, 905-911.	1.3	24
49	Dosimetry in clinical radionuclide therapy: the devil is in the detail. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1-3.	6.4	35
50	Zalecenia ogÃ³lne dotyczÄ…ce postÄ™powania diagnostyczno-terapeutycznego w nowotworach neuroendokrynnych ukÅ‚adu pokarmowego (rekomendowane przez PolskÄ… SieÄ‡ GuzÃ³w) Tj ETQq0 0 0 rgBT /Overlock 10	1.0	40
51	Nowotwory neuroendokrynne Å¼oÅ‚Ä…dka i dwunastnicy z uwzglÄ™dnieniem gastrinoma (zasady postÄ™powania) Tj ETQq1 1 0.7	1.0	20
52	Nowotwory neuroendokrynne jelita cienkiego i wyrostka robaczkowego â€" zasady postÄ™powania (rekomendowane przez PolskÄ… SieÄ‡ GuzÃ³w Neuroendokrynnych). Endokrynologia Polska, 2017, 68, 223-236.	1.0	18
53	Nowotwory neuroendokrynne jelita grubego â€" zasady postÄ™powania (rekomendowane przez PolskÄ… SieÄ‡) Tj ETQq1 1 0.7843	1.0	20
54	Nowotwory neuroendokrynne trzustki â€" zasady diagnostyki i leczenia (rekomendowane przez PolskÄ…) Tj ETQq0 0 0 rgBT /Overlock	1.0	11

#	Article	IF	Citations
55	⁶⁸Ga-DOTATATE PET in juvenile angiofibroma. Future Oncology, 2016, 12, 1483-1491.	2.4	10
56	Rak rdzeniasty tarczycy â€" badanie PET/CT ze znakowanymi 68Ga analogami gastryny i somatostatyny. Endokrynologia Polska, 2016, 67, 68-71.	1.0	15
57	Diagnostic Accuracy of Contrast-Enhanced Computed Tomography and Positron Emission Tomography With 18-FDG in Identifying Malignant Solitary Pulmonary Nodules. Medicine (United States), 2015, 94, e666.	1.0	21
58	Jak czÄ™sto wykrywamy przypadkowe zmiany w tarczycy w badaniu PET/CT z 68Ga-DOTATATE u pacjentÃ³w diagnozowanych z powodu nowotworu neuroendokrynnego?. Endokrynologia Polska, 2015, 66, 231-236.	1.0	9
59	What parameters from 18F-FDG PET/CT are useful in evaluation of adrenal lesions?. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 2273-2280.	6.4	49
60	A Frequency and Semiquantitative Analysis of Pathological 68Ga DOTATATE PET/CT Uptake by Primary Siteâ€"Dependent Neuroendocrine Tumor Metastasis. Clinical Nuclear Medicine, 2014, 39, 855-861.	1.3	13
61	Response to comment by Aprile et al.: The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1259-1260.	6.4	5
62	Retroperitoneal Pheochromocytoma With Thorax and Bilateral Neck Chemodectoma in Patients With Multiorgan Sarcoidosis. Clinical Nuclear Medicine, 2014, 39, e258-e262.	1.3	1
63	Zalecenia ogÃ³lne dotyczÄ...ce postÄ™powania w nowotworach neuroendokrynnych ukÅ‚adu pokarmowego (rekomendowane przez PolskÄ... SieÄ‡ GuzÃ³w Neuroendokrynnych). Endokrynologia Polska, 2014, 64, 418-443.	1.0	42
64	Nowotwory neuroendokrynne jelita cienkiego i wyrostka robaczkowego â€" zasady postÄ™powania (rekomendowane przez PolskÄ... SieÄ‡ GuzÃ³w Neuroendokrynnych). Endokrynologia Polska, 2014, 64, 480-493.	1.0	25
65	Nowotwory neuroendokrynne Å¼oÅ‚Ä...dka i dwunastnicy z uwzglÄ™dnieniem gastrinoma â€" zasady postÄ™powania (rekomendowane przez PolskÄ... SieÄ‡ GuzÃ³w Neuroendokrynnych). Endokrynologia Polska, 2014, 64, 444-458.	1.0	7
66	Nowotwory neuroendokrynne trzustki â€" zasady postÄ™powania (rekomendowane przez PolskÄ... SieÄ‡ GuzÃ³w) Tj ETQq0 0 0 rgBT /	1.0	13
67	Nowotwory neuroendokrynne jelita grubego â€" zasady postÄ™powania (rekomendowane przez PolskÄ... SieÄ‡) Tj ETQq1 1 0.78431	1.0	11
68	Radioguided surgery in patient with pancreatic neuroendocrine tumour followed by PET/CT scan as a new approach of complete resection evaluation â€" case report. Nuclear Medicine Review, 2014, 17, 108-109.	0.5	4
69	Accuracy of FDG PET/CT in the evaluation of solitary pulmonary lesions â€" own experience. Pneumonologia I Alergologia Polska, 2014, 82, 198-205.	0.6	11
70	Nietypowy przypadek przebiegu nowotworu neuroendokrynnego trzustki pod postaciÄ... przerzutu do serca â€" opis przypadku klinicznego. Endokrynologia Polska, 2014, 65, 232-239.	1.0	1
71	The first â€œBest Paper of Nuclear Medicine Reviewâ€•session at the XIV International Congress of the Polish Society of Nuclear Medicine 28â€"30th of May 2014. Nuclear Medicine Review, 2014, 17, 121-122.	0.5	0
72	Radioiodine therapy in patients with type II amiodaroneâ€'induced thyrotoxicosis. Polish Archives of Internal Medicine, 2014, 124, 695-703.	0.4	5

#	Article	IF	Citations
73	The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1932-1947.	6.4	228
74	Polish Experience in Peptide Receptor Radionuclide Therapy. Recent Results in Cancer Research, 2013, 194, 467-478.	1.8	9
75	Different technical possibilities of post- -therapeutic tandem 90Y/ /177Lu-DOTATATE imaging. Nuclear Medicine Review, 2013, 16, 70-74.	0.5	3
76	Nephrotoxicity after PRRT - still a serious clinical problem? Renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATATE and 90Y/177Lu-DOTATATE. Endokrynologia Polska, 2013, 64, 13-20.	1.0	3
77	Semiquantitative Analysis and Characterization of Physiological Biodistribution of 68Ga-DOTA-TATE PET/CT. Clinical Nuclear Medicine, 2012, 37, 1052-1057.	1.3	43
78	Repeated cycles of peptide receptor radionuclide therapy (PRRT) â€“ Results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET. Radiotherapy and Oncology, 2012, 102, 45-50.	0.6	39
79	Statins Impair Glucose Uptake in Tumor Cells. Neoplasia, 2012, 14, 311-323.	5.3	37
80	A non-functioning pancreatic neuroendocrine tumour: a case report. Endokrynologia Polska, 2012, 63, 59-64.	1.0	1
81	Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1788-1797.	6.4	211
82	Efficacy and safety of 90Y-DOTATATE therapy in neuroendocrine tumours. Endokrynologia Polska, 2011, 62, 392-400.	1.0	7
83	Neuroendocrine tumours of rare location. Endokrynologia Polska, 2010, 61, 322-7.	1.0	5
84	Elevated D-dimer concentration identifies patients with incomplete recanalization of pulmonary artery thromboemboli despite 6Âmonths anticoagulation after the first episode of acute pulmonary embolism. Thrombosis Research, 2008, 122, 21-25.	1.7	25
85	New forms of radionuclide therapy with (90)Y in oncology. Nuclear Medicine Review, 2008, 11, 5-11.	0.5	3
86	Determination of left ventricular ejection fraction by gated 99mTc-sestamibi SPECT--correlation with coronary angiography. Acta Cardiologica, 2002, 57, 49-51.	0.9	0
87	2022 follow-up: impact of the COVID-19 pandemic on nuclear medicine departments in Europe. European Journal of Nuclear Medicine and Molecular Imaging, 0, , .	6.4	2